Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval

MT Newswires Live

06/01

Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-K for the year ended Dec. 31, 2025, which includes the 2024 audit.

The company said it believes the audit is in its final stages of approval.

Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.

The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.

Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2640558259"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640558259\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640558259?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640558259","market":"nz","top_or_hot":-1,"title":"Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval","media":"MT Newswires Live","content":"<html><body><p> Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the year ended Dec. 31, 2025, which includes the 2024 audit.</p><p>The company said it believes the audit is in its final stages of approval.</p><p>Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.</p><p>The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.</p><p>Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGreenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-01 18:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the year ended Dec. 31, 2025, which includes the 2024 audit.</p><p>The company said it believes the audit is in its final stages of approval.</p><p>Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.</p><p>The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.</p><p>Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLSI","symbol_name":"Greenwich Lifesciences Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640558259","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640558259","pubTimestamp":1780310925,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Greenwich LifeSciences  said Monday its new auditor continues to audit the company's Form 10-K for the year ended Dec. 31, 2025, which includes the 2024 audit.The company said it believes the audit is in its final stages of approval.Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLSI":"Greenwich Lifesciences Inc","BK4139":"生物科技"},"translate_title":"Greenwich LifeSciences表示对2025年10-K表格备案的审计已进入批准的最后阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLSI":1},"content_text":"Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-K for the year ended Dec. 31, 2025, which includes the 2024 audit.The company said it believes the audit is in its final stages of approval.Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}